Clinical Trial Update: Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF). [Phase 2]

View source ↗

Summary

A Phase 2 dose-escalation trial evaluating KW-3902 for diuresis in subjects with congestive heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• KW-3902

Snippet

Sponsor: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Heart Failure, Congestive | Phase 2 | Status: COMPLETED